Fluvastin therapy affects TAFI concentration in kidney transplant recipients

Abstract Thrombin activatable fibrinolysis inhibitor (TAFI) is a glycoprotein, linking coagulation and fibrinolysis. Recently, attention has been drawn to the beneficial effects of statins on haemostasis in kidney patients prone to dyslipidaemia and with a high risk of cardiovascular death. The purpose of this study was to assess whether fluvastatin affects TAFI concentration in renal transplant recipients. We evaluated thrombin–antithrombin (TAT) complexes, prothrombin fragments 1+2, thrombomodulin, plasmin–antiplasmin (PAP) complexes, TAFI, P-selectin, and lipoprotein (a), 1, 2, and 3 months before and after fluvastatin treatment and in normolipaemic kidney transplant recipients and healthy volunteers. Cholesterol and LDL fell significantly as soon as 1 month after treatment had begun and remained lowered during the therapy. TAFI and prothrombin fragments 1+2 decreased significantly after 3 months of fluvastatin administration, whereas P-selectin decreased significantly after 2 months and remained significantly lower after 3 months of this therapy. We can conclude that fluvastatin is an effective hypolipaemic agent that favourably affects haemostasis.

[1]  J. Małyszko,et al.  Simvastain Affects TAFI and Thrombomodulin in CAPD Patients , 2001, Thrombosis and Haemostasis.

[2]  M. Myśliwiec,et al.  A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  P. Ridker,et al.  Soluble P-Selectin and the Risk of Future Cardiovascular Events , 2001, Circulation.

[4]  M. Wolzt,et al.  Similar Effects of Atorvastatin, Simvastatin and Pravastatin on Thrombogenic and Inflammatory Parameters in Patients with Hypercholesterolemia , 2001, Thrombosis and Haemostasis.

[5]  F. Rosendaal,et al.  Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. , 2000, Blood.

[6]  G. Habib,et al.  Fluvastatin Decreases Soluble Thrombomodulin in Cardiac Transplant Recipients , 2000, Thrombosis and Haemostasis.

[7]  J. Harenberg,et al.  Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. , 1999, Thrombosis research.

[8]  F. Locatelli,et al.  Morbidity and Mortality on Maintenance Haemodialysis , 1998, Nephron.

[9]  M. Boffa,et al.  A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor* , 1998, The Journal of Biological Chemistry.

[10]  B. Fagerberg,et al.  Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men , 1998, Journal of hypertension.

[11]  J. Morser,et al.  Both Cellular and Soluble Forms of Thrombomodulin Inhibit Fibrinolysis by Potentiating the Activation of Thrombin-activable Fibrinolysis Inhibitor* , 1998, The Journal of Biological Chemistry.

[12]  T. Hayek,et al.  Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. , 1998, Journal of cardiovascular pharmacology.

[13]  M. Boffa,et al.  Thrombin, Thrombomodulin and TAFI in the Molecular Link Between Coagulation and Fibrinolysis , 1997, Thrombosis and Haemostasis.

[14]  G. Lip,et al.  Hypothesis: is soluble P-selectin a new marker of platelet activation? , 1997, Atherosclerosis.

[15]  J. Małyszko,et al.  The coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipients. , 1996, Transplantation.

[16]  D. Pawlak,et al.  Platelet aggregation and peripheral serotonergic system in kidney transplant recipients treated with cyclosporine. , 1996, Transplantation proceedings.

[17]  R. Stein,et al.  Comparison of ST-segment/heart rate slope analysis with standard ST-segment measurement criteria to outcome of exercise thallium-201 imaging. , 1995, The American journal of cardiology.

[18]  R. Goldberg,et al.  A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. , 1995, The American journal of cardiology.

[19]  D. Di Landro,et al.  Reduced fibrinolytic potential one year after kidney transplantation. Relationship to long-term steroid treatment. , 1995, Transplantation.

[20]  M. H. Gault,et al.  Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. , 1995, Nephron.

[21]  R. Knöfler,et al.  Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. , 1994, Thrombosis research.

[22]  S. Knechtle,et al.  Hyperlipidemia and transplantation: etiologic factors and therapy. , 1992, Journal of the American Society of Nephrology : JASN.

[23]  P. Newman,et al.  Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes. , 1990, The Journal of biological chemistry.

[24]  J. Loscalzo,et al.  Lipoprotein(a). A unique risk factor for atherothrombotic disease. , 1990, Arteriosclerosis.

[25]  I. Kovács,et al.  Enhanced in vitro hemostasis and reduced thrombolysis in cyclosporine-treated renal transplant recipients. , 1990, Transplantation.

[26]  K. Schrör.  Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinaemia and its modification by cholesterol-lowering agents. , 1990, Eicosanoids.

[27]  Z. Varghese,et al.  Dietary fish oil supplements preserve renal function in renal transplant recipients with chronic vascular rejection. , 1989, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  T. Lerut,et al.  THROMBOEMBOLIC COMPLICATIONS AND HAEMOSTATIC CHANGES IN CYCLOSPORIN-TREATED CADAVERIC KIDNEY ALLOGRAFT RECIPIENTS , 1985, The Lancet.